Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Kristin G Anderson"'
Autor:
Philip D Greenberg, Valentin Voillet, Raphael Gottardo, Kristin G Anderson, Breanna M Bates, Madison G Burnett, Susan L Ruskin, Yapeng Su, Magdalia L Suarez Gutierrez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/02aa15847e644c8caf9301b40b6a786b
Autor:
Fan Zhang, Brendan Horton, Marco Ruella, Vivek Verma, Abigail Overacre-Delgoffe, Kristin G Anderson, Jennifer L Guerriero, Teresa S Kim, David A Braun, Aitziber Buqué, Sarah B Gitto, Bridget P Keenan, Todd A Triplett, Omkara Veeranki
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Anticancer immunotherapies, such as immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells, have improved outcomes for patients with a variety of malignancies. However, most patients either do not initially respond
Externí odkaz:
https://doaj.org/article/17b8d13024474665bb006c0638125376
Autor:
Philip D Greenberg, Kristin G Anderson, Shannon K Oda, Breanna M Bates, Madison G Burnett, Magdalia Rodgers Suarez, Susan L Ruskin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background In the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations. Mesothelin (MSLN) is a candidate immunotherapy target; it is overexpressed by ovarian tumors and
Externí odkaz:
https://doaj.org/article/16c482feb17b4df89dbc5b52b72fb431
Autor:
Daniel Olson, Jiajia Zhang, Todd Bartkowiak, Abdul Rafeh Naqash, Vaia Florou, Rosa Nguyen, Rania H Younis, Sarah Church, Maria E Rodriguez-Ruiz, Rachel Howard, Thomas U Marron, Ravi B Patel, Michal Sheffer, Abigail Overacre-Delgoffe, Aideen E Ryan, Sangeetha M Reddy, Sabina Kaczanowska, Dipti Thakkar, Kristin G Anderson, Esha Sachdev, Christopher Fuhrman, Jessica E Thaxton, David H Aggen, Jennifer L Guerriero
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the tim
Externí odkaz:
https://doaj.org/article/7d235762c1ba404981eaf9960cd816b9
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Figure S2: Engineered murine T cells exhibit effector function in response to cognate peptide.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cbf43fa751a120f7f60ec30f7643f8c
https://doi.org/10.1158/2326-6066.22543435
https://doi.org/10.1158/2326-6066.22543435
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Figure Legends for Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975efb2816191d40d7b2661b26c8ea6e
https://doi.org/10.1158/2326-6066.22543414.v1
https://doi.org/10.1158/2326-6066.22543414.v1
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Adoptive T-cell therapy using high-affinity T-cell receptors (TCR) to target tumor antigens has potential for improving outcomes in high-grade serous ovarian cancer (HGSOC) patients. Ovarian tumors develop a hostile, multicomponent tumor microenviron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c02eecee4fe98f8dd53a22107cf78629
https://doi.org/10.1158/2326-6066.c.6550249.v1
https://doi.org/10.1158/2326-6066.c.6550249.v1
Autor:
Philip D. Greenberg, Raphael Gottardo, Charles W. Drescher, Ingunn M. Stromnes, Christopher B. Morse, Shannon K. Oda, Nicolas M. Garcia, Madison G. Burnett, Edison Y. Chiu, Breanna M. Bates, Valentin Voillet, Kristin G. Anderson
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3295f8a853f8db1a76312f1d72d071c9
https://doi.org/10.1158/2326-6066.22543411
https://doi.org/10.1158/2326-6066.22543411
Autor:
Philip D. Greenberg, Shannon K. Oda, Breanna M. Bates, Susan L. Ruskin, Kristin G. Anderson, Madison G. Burnett, Magdalia Rodgers Suarez
BackgroundIn the U.S., more than 50% of ovarian cancer patients die within 5 years of diagnosis, highlighting the need for innovations such as engineered T cell therapies. Mesothelin (Msln) is an attractive immunotherapy target for this cancer, as it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::794c480b791954a026fe52e6f7d6fbda
https://doi.org/10.1101/2021.07.30.454539
https://doi.org/10.1101/2021.07.30.454539
Autor:
Shannon K. Oda, Raphael Gottardo, Philip D. Greenberg, Valentin Voillet, Madison G. Burnett, Edison Y. Chiu, Ingunn M. Stromnes, Christopher B. Morse, Kristin G. Anderson, Charles W. Drescher, Breanna M. Bates, Nicolas M. Garcia
Publikováno v:
Cancer Immunology Research. 7:1412-1425
Adoptive T-cell therapy using high-affinity T-cell receptors (TCR) to target tumor antigens has potential for improving outcomes in high-grade serous ovarian cancer (HGSOC) patients. Ovarian tumors develop a hostile, multicomponent tumor microenviron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b83e5594f1624efe9e5bd14aed8e502
https://doi.org/10.1158/2326-6066.cir-19-0258
https://doi.org/10.1158/2326-6066.cir-19-0258